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In this letter, we update the data on the worldwide expan-
sion of chikungunya virus (CHIKV), with a focus on the burden
of chikungunya in the Paciﬁc.G. 1. Countries/territories with reported local transmission of chikunguny
11–2015 (b).
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This is an open access artiChikungunya emerged in the Paciﬁc in 2011, and is now
spreading throughout the region.
In February 2011, CHIKV was detected for the ﬁrst time in
the Paciﬁc in New Caledonia (33 autochthonous cases), sub-
sequently to cases being imported from Indonesia [1].
In June 2012, a CHIKV outbreak started in Papua New
Guinea; it lasted until 2013, with >1500 reported cases [1].
In 2013, an increase in the rate of spread of CHIKV was
observed, with new outbreaks being reported: a second
epidemic started in New Caledonia in April (30 autochthonous
cases) following a new introduction from Indonesia, and
another outbreak started in Yap State (Federated States of
Micronesia) in August [1].
In 2014, CHIKV epidemics were reported in Tonga, Amer-
ican Samoa, Independent States of Samoa, and Tokelau [2]. In
October 2014, a large CHIKV outbreak started in French
Polynesia, with 66 000 estimated cases (~25% of the popula-
tion) as of January 2015 [2,3]; this outbreak reached all of the
archipelagoes of French Polynesia, and is still ongoing. Phylo-
genic studies demonstrated that CHIKV was probably intro-
duced to French Polynesia from the Caribbean, and not from
other Paciﬁc countries [2]. CHIKV re-emerged in New Cale-
donia [2] following multiple introductions from French Poly-
nesia; 27 imported and two autochthonous cases were
reported in mid-December 2014.
In January 2015, local transmission of CHIKV has been re-
ported in the Cook Islands [3].a virus in the world (a), with a focus on recent emergence in the Paciﬁc
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ported in Queensland (Australia) from Papua New Guinea, in
New Zealand from Tonga, in Niue from Independent States of
Samoa, and in New Caledonia from French Polynesia.
Two CHIKV lineages have been detected in the Paciﬁc: the
Asian lineage in most of the islands, and the East/Central/South
African lineage in Papua New Guinea in 2012 [2].
Before 2011, the 22 Paciﬁc Islands Countries and Territories
were presumed to be free of chikungunya. Within the last 3
years, autochthonous CHIKV infections have been reported in
nine of these countries (Fig. 1).
The main favourable conditions contributing to the spread of
CHIKV in the Paciﬁc are the intensiﬁcation of travel exchange,
climatic conditions and climate warming, and the distribution of
Aedes aegypti and other competent mosquito vectors for
CHIKV, such as Aedes albopictus and Aedes polynesiensis [4].
CHIKV has the potential to spread throughout the whole
Paciﬁc, and to reach close countries that contain competent
vectors.
A unique feature of the emergence of arboviruses in the
Paciﬁc is the circulation in recent years of the four dengue virus
serotypes, Zika virus, and CHIKV. The peak of co-circulation
was in 2014: CHIKV was detected in eight of the 22 Paciﬁc
Islands Countries and Territories, Zika virus in four, and dengue
virus in eight [5]. However, owing to limited laboratory capacity
in the Paciﬁc, the global incidence and prevalence of arbovirus
infections are unknown and the burden of these diseases is
potentially underestimated.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
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changed, from a relatively uncommon and poorly documented
disease, to an emerging disease, and now to a global public
health concern. CHIKV now circulates in all of the inhabited
continents (North and South America, Europe, Africa, Asia, and
Oceania), which conﬁrms the globalization of the disease.Transparency declarationThe authors declare that there are no conﬂicts of interest.References[1] Roth A, Hoy D, Horwood PF, Ropa B, Hancock T, Guillaumot L, et al.
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